{
  "model": "chatgpt-gpt-5.3-codex-spark",
  "agentReasoning": "medium",
  "taskId": "tumor-vaccine-ici",
  "runIndex": 1,
  "workspacePath": "workspaces/chatgpt-gpt-5-3-codex-spark-tumor-vaccine-ici-run-1",
  "success": true,
  "schemaPass": true,
  "toolTracePass": true,
  "graderPass": true,
  "durationMs": 65931,
  "agentCostUsd": 0.04394135,
  "graderCostUsd": 0.01668975,
  "totalCostUsd": 0.06063109999999999,
  "agentUsage": {
    "promptTokens": 133423,
    "cachedTokens": 113664,
    "responseTokens": 5503,
    "thinkingTokens": 12577,
    "totalTokens": 151503
  },
  "graderUsage": {
    "promptTokens": 4281,
    "cachedTokens": 0,
    "responseTokens": 183,
    "thinkingTokens": 474,
    "totalTokens": 4938
  },
  "totalUsage": {
    "promptTokens": 137704,
    "cachedTokens": 113664,
    "responseTokens": 5686,
    "thinkingTokens": 13051,
    "totalTokens": 156441
  },
  "modelVersions": [
    "chatgpt-gpt-5.3-codex-spark"
  ],
  "agentFinalText": "✅ **Completed output files**\n\n- [x] `output/study_overview.json`\n- [x] `output/quantitative_findings.json`\n- [x] `output/claim_audit.json`\n- [x] `output/public_summary.json`",
  "outputValidation": [
    {
      "outputFile": "output/study_overview.json",
      "schemaFile": "schemas/study_overview.schema.json",
      "exists": true,
      "jsonValid": true,
      "schemaValid": true,
      "groundingValid": true,
      "errors": [],
      "content": "{\n  \"paper\": {\n    \"title\": \"SARS-CoV-2 mRNA vaccines sensitize tumours to immune checkpoint blockade\",\n    \"doi\": \"10.1038/s41586-025-09006-8\",\n    \"publication_year\": 2025,\n    \"domain\": \"oncology-immunology\",\n    \"study_type\": \"preclinical+retrospective\"\n  },\n  \"core_question\": \"Can intratumoral mRNA vaccination increase tumor sensitivity to anti-PD-L1 immune checkpoint blockade, and are the findings consistent in both murine models and retrospective human ICI-treated patients?\",\n  \"datasets_or_cohorts\": [\n    {\n      \"id\": \"mouse-efficacy-cohort\",\n      \"label\": \"Mouse efficacy cohort\",\n      \"sample_size_or_observations\": \"78 mice (pooled across repeat experiments)\",\n      \"description\": \"Murine efficacy studies testing intratumoral mRNA vaccination combined with anti-PD-L1 in multiple tumor models.\"\n    },\n    {\n      \"id\": \"mouse-control-cohort\",\n      \"label\": \"Mouse control cohort\",\n      \"sample_size_or_observations\": \"84 mice (pooled across matched controls)\",\n      \"description\": \"Matched murine controls receiving vaccine-only, ICI-only, and vehicle treatment for comparison against sensitization outcomes.\"\n    },\n    {\n      \"id\": \"human-retrospective-cohort\",\n      \"label\": \"Human retrospective cohort\",\n      \"sample_size_or_observations\": \"130 metastatic patients\",\n      \"description\": \"Metastatic patients receiving immune checkpoint inhibitors, analyzed retrospectively by prior SARS-CoV-2 mRNA vaccination status.\"\n    },\n    {\n      \"id\": \"human-vaccinated-subgroup\",\n      \"label\": \"Human vaccinated subgroup\",\n      \"sample_size_or_observations\": \"43 patients\",\n      \"description\": \"Subset of the retrospective cohort previously vaccinated with a SARS-CoV-2 mRNA vaccine before/around ICI treatment.\"\n    },\n    {\n      \"id\": \"human-unvaccinated-subgroup\",\n      \"label\": \"Human unvaccinated subgroup\",\n      \"sample_size_or_observations\": \"87 patients\",\n      \"description\": \"Comparison group of metastatic patients without documented SARS-CoV-2 mRNA vaccination for survival and clinical outcome contrasts.\"\n    }\n  ],\n  \"major_limitations\": [\n    \"The human analysis is retrospective and non-randomized, so residual confounding is likely. \",\n    \"Vaccination timing relative to ICI initiation varied across patients. \",\n    \"Tumor-type mix and treatment-history heterogeneity limit direct causal interpretation. \",\n    \"Mouse model effects may not map one-to-one to all human tumors. \",\n    \"Some mechanistic readouts were strongest in specific model systems rather than uniformly across all settings. \"\n  ]\n}"
    },
    {
      "outputFile": "output/quantitative_findings.json",
      "schemaFile": "schemas/quantitative_findings.schema.json",
      "exists": true,
      "jsonValid": true,
      "schemaValid": true,
      "groundingValid": true,
      "errors": [],
      "content": "{\n  \"findings\": [\n    {\n      \"id\": \"Q01\",\n      \"metric\": \"Tumor immunopeptidome breadth\",\n      \"value\": \"62.3% vs 37.3%\",\n      \"comparator_or_baseline\": \"vaccine/combination arm versus comparator condition\",\n      \"interpretation\": \"Intratumoral mRNA-vaccinated or combination-treated tumors showed a notably larger fraction of proteins represented in the immunopeptidome, indicating broader antigen display.\",\n      \"evidence_line_refs\": [\"L28\"]\n    },\n    {\n      \"id\": \"Q02\",\n      \"metric\": \"MHC-I peptide landscape breadth\",\n      \"value\": \"40.6% vs 20.6%\",\n      \"comparator_or_baseline\": \"combination or vaccine arm versus comparator\",\n      \"interpretation\": \"MHC-I-presented proteins roughly doubled, supporting expansion of the antigenic peptide repertoire potentially more visible to CD8+ responses.\",\n      \"evidence_line_refs\": [\"L29\"]\n    },\n    {\n      \"id\": \"Q03\",\n      \"metric\": \"Retrospective survival association under ICI\",\n      \"value\": \"p=0.01\",\n      \"comparator_or_baseline\": \"vaccinated versus unvaccinated subgroup\",\n      \"interpretation\": \"Vaccinated patients in the metastatic cohort had improved survival compared with unvaccinated patients under ICI treatment, reaching the reported significance threshold.\",\n      \"evidence_line_refs\": [\"L30\", \"L21\", \"L23\"]\n    },\n    {\n      \"id\": \"Q04\",\n      \"metric\": \"Type I interferon response score\",\n      \"value\": \"3.1 normalized units\",\n      \"comparator_or_baseline\": \"1.0 baseline normalized units\",\n      \"interpretation\": \"The reported normalized interferon response increased after intratumoral mRNA vaccination, consistent with innate activation in tumors.\",\n      \"evidence_line_refs\": [\"L31\"]\n    },\n    {\n      \"id\": \"Q05\",\n      \"metric\": \"PD-L1 expression change\",\n      \"value\": \"2.4x\",\n      \"comparator_or_baseline\": \"1.0x baseline\",\n      \"interpretation\": \"PD-L1 levels increased in tumor tissue, supporting the biologic rationale for combining with checkpoint blockade.\",\n      \"evidence_line_refs\": [\"L32\"]\n    },\n    {\n      \"id\": \"Q06\",\n      \"metric\": \"Intratumoral CD8+ T-cell density\",\n      \"value\": \"1.8x\",\n      \"comparator_or_baseline\": \"1.0x baseline\",\n      \"interpretation\": \"CD8+ T-cell density increased approximately 1.8-fold, consistent with improved immune infiltration after sensitization strategies.\",\n      \"evidence_line_refs\": [\"L33\"]\n    },\n    {\n      \"id\": \"Q07\",\n      \"metric\": \"Mouse sample size\",\n      \"value\": \"78 mice efficacy / 84 mice controls\",\n      \"comparator_or_baseline\": \"pooled across repeat experiments and matched controls\",\n      \"interpretation\": \"The preclinical evidence combines substantial mouse observations from both efficacy and control arms to contrast treatment combinations and controls.\",\n      \"evidence_line_refs\": [\"L19\", \"L20\"]\n    }\n  ],\n  \"controls_or_null_results\": [\n    {\n      \"statement\": \"Vaccine-only treatment did not produce durable tumor control in non-immunogenic models.\",\n      \"evidence_line_ref\": \"L36\"\n    },\n    {\n      \"statement\": \"ICI-only treatment had limited activity in low-immunogenic baseline settings.\",\n      \"evidence_line_ref\": \"L37\"\n    },\n    {\n      \"statement\": \"Lipid particle controls lacking mRNA did not reproduce sensitization benefits.\",\n      \"evidence_line_ref\": \"L38\"\n    },\n    {\n      \"statement\": \"Blocking type I interferon signaling with anti-IFNAR1 eliminated the sensitization benefit.\",\n      \"evidence_line_ref\": \"L39\"\n    }\n  ]\n}"
    },
    {
      "outputFile": "output/claim_audit.json",
      "schemaFile": "schemas/claim_audit.schema.json",
      "exists": true,
      "jsonValid": true,
      "schemaValid": true,
      "groundingValid": true,
      "errors": [],
      "content": "{\n  \"claims\": [\n    {\n      \"claim_id\": \"C01\",\n      \"claim\": \"Intratumoral mRNA vaccination can broaden tumor antigen presentation and increase immune visibility.\",\n      \"strength\": \"strong\",\n      \"evidence\": [\n        {\n          \"quote\": \"Broader antigen display after intratumoral mRNA vaccination\",\n          \"line_ref\": \"L28\"\n        },\n        {\n          \"quote\": \"A broader peptide repertoire appears on MHC-I, improving tumor visibility to T cells.\",\n          \"line_ref\": \"L44\"\n        }\n      ],\n      \"caveat\": \"Mechanistic readouts were not uniformly strong across all tested model systems, so effect size may vary by context.\"\n    },\n    {\n      \"claim_id\": \"C02\",\n      \"claim\": \"The treatment strategy induces type I interferon-associated signaling and increases PD-L1 pathway activity, supporting combination with checkpoint blockade.\",\n      \"strength\": \"strong\",\n      \"evidence\": [\n        {\n          \"quote\": \"Type I interferon response score (normalized units) | 3.1 | 1.0 | Marked induction after mRNA vaccination in tumors\",\n          \"line_ref\": \"L31\"\n        },\n        {\n          \"quote\": \"Interferon-associated antigen processing and presentation pathways increase.\",\n          \"line_ref\": \"L43\"\n        },\n        {\n          \"quote\": \"PD-L1 pathway activity also increases, creating a rationale for combining with checkpoint blockade.\",\n          \"line_ref\": \"L45\"\n        }\n      ],\n      \"caveat\": \"The report emphasizes that some mechanistic readouts were strongest in specific models rather than universal across all settings.\"\n    },\n    {\n      \"claim_id\": \"C03\",\n      \"claim\": \"Combination of intratumoral mRNA vaccine and anti-PD-L1 produced stronger antitumor immune signatures than controls in the preclinical murine arm.\",\n      \"strength\": \"moderate\",\n      \"evidence\": [\n        {\n          \"quote\": \"Preclinical arm: multiple murine tumor models with intratumoral mRNA vaccine and anti-PD-L1 combinations.\",\n          \"line_ref\": \"L14\"\n        },\n        {\n          \"quote\": \"Intratumoral CD8+ T-cell density fold-change | 1.8x | 1.0x | Increased immune infiltration with combination therapy\",\n          \"line_ref\": \"L33\"\n        }\n      ],\n      \"caveat\": \"Response-level details and statistical analyses for each model are not fully enumerated in the summary, limiting certainty about magnitude across tumors.\"\n    },\n    {\n      \"claim_id\": \"C04\",\n      \"claim\": \"Vaccinated metastatic patients showed an associated survival advantage under ICI treatment compared with unvaccinated patients in the retrospective cohort.\",\n      \"strength\": \"tentative\",\n      \"evidence\": [\n        {\n          \"quote\": \"Retrospective human survival comparison p-value | p=0.01 | N/A | Vaccinated subgroup had improved survival under ICI treatment\",\n          \"line_ref\": \"L30\"\n        },\n        {\n          \"quote\": \"The human analysis is retrospective and non-randomized; residual confounding is likely.\",\n          \"line_ref\": \"L49\"\n        }\n      ],\n      \"caveat\": \"Because the cohort analysis is non-randomized with variable vaccination timing and treatment heterogeneity, causality cannot be inferred.\"\n    }\n  ]\n}"
    },
    {
      "outputFile": "output/public_summary.json",
      "schemaFile": "schemas/public_summary.schema.json",
      "exists": true,
      "jsonValid": true,
      "schemaValid": true,
      "groundingValid": true,
      "errors": [],
      "content": "{\n  \"headline\": \"Intratumoral mRNA vaccination may make tumors more responsive to anti-PD-L1 therapy\",\n  \"plain_language_summary\": \"Researchers tested whether delivering an mRNA vaccine directly into a tumor could sensitize cancers to immune checkpoint blockade. In multiple mouse models, adding intratumoral mRNA vaccination to anti-PD-L1 therapy was associated with broader tumor antigen presentation, higher type I interferon signaling, increased PD-L1 levels, and greater intratumoral CD8+ T-cell density. In a retrospective review of 130 metastatic patients treated with ICI, 43 vaccinated patients had better survival than 87 unvaccinated patients, with a reported p-value of 0.01. The study also showed that the benefit depended on interferon signaling and was lost when IFNAR1 signaling was blocked, and that non-mRNA particle controls did not reproduce the effect. The authors note this was preclinical plus retrospective evidence, so prospective randomized trials are still needed before clinical decisions can change.\",\n  \"what_is_new\": [\n    \"A local mRNA vaccine strategy appears to broaden both the immunopeptidome and MHC-I peptide presentation in tumors, potentially improving immune recognition.\",\n    \"The work connects mechanistic murine evidence with a human retrospective association, suggesting a biologic rationale and a clinical signal from the same intervention concept.\",\n    \"The report identifies type I interferon signaling as an essential mediator, with anti-IFNAR1 blockade removing the sensitization benefit and mRNA-free lipid particles failing to mimic it.\"\n  ],\n  \"why_caution_is_needed\": [\n    \"The human comparison was retrospective and non-randomized, so unmeasured confounding and baseline differences could influence survival associations.\",\n    \"Vaccination timing relative to ICI start varied among patients, which weakens causal interpretation of the survival signal.\",\n    \"Tumor types and prior treatment histories were mixed, and mouse model findings may not translate uniformly across all human cancers.\"\n  ],\n  \"glossary\": [\n    {\n      \"term\": \"ICI\",\n      \"definition\": \"Immune checkpoint inhibitors such as anti-PD-L1 that remove inhibitory signaling and can reactivate T-cell anti-tumor activity.\"\n    },\n    {\n      \"term\": \"PD-L1\",\n      \"definition\": \"A checkpoint ligand on tumor cells that can suppress T-cell function; anti-PD-L1 therapy blocks this inhibitory signal.\"\n    },\n    {\n      \"term\": \"MHC-I\",\n      \"definition\": \"A major histocompatibility complex class I molecule that presents peptides to CD8+ T-cells for immune recognition.\"\n    },\n    {\n      \"term\": \"Immunopeptidome\",\n      \"definition\": \"The set of peptides presented by MHC molecules on a cell, used as a readout of antigen visibility to the immune system.\"\n    }\n  ],\n  \"open_questions\": [\n    \"Can these findings be confirmed in a prospective randomized trial with fixed vaccine timing and standardized ICI regimens?\",\n    \"Which tumor histologies and prior treatment backgrounds benefit most from this sensitization strategy, and which derive little benefit?\",\n    \"Can interferon and antigen-presentation signatures be used as practical biomarkers to select patients likely to respond?\"\n  ]\n}"
    }
  ],
  "toolTrace": {
    "pass": true,
    "totalCalls": 40,
    "failedCalls": 0,
    "toolsUsed": [
      "grep_search",
      "list_directory",
      "read_file",
      "write_file"
    ],
    "hasSuccessfulRead": true,
    "hasSuccessfulWrite": true,
    "pathPolicyViolations": [],
    "notes": [],
    "calls": [
      {
        "source": "llm",
        "step": 1,
        "toolName": "list_directory"
      },
      {
        "source": "llm",
        "step": 2,
        "toolName": "read_file"
      },
      {
        "source": "llm",
        "step": 3,
        "toolName": "list_directory"
      },
      {
        "source": "llm",
        "step": 4,
        "toolName": "read_file"
      },
      {
        "source": "llm",
        "step": 5,
        "toolName": "read_file"
      },
      {
        "source": "llm",
        "step": 6,
        "toolName": "read_file"
      },
      {
        "source": "llm",
        "step": 7,
        "toolName": "read_file"
      },
      {
        "source": "llm",
        "step": 8,
        "toolName": "read_file"
      },
      {
        "source": "llm",
        "step": 9,
        "toolName": "write_file"
      },
      {
        "source": "llm",
        "step": 10,
        "toolName": "write_file"
      },
      {
        "source": "llm",
        "step": 11,
        "toolName": "write_file"
      },
      {
        "source": "llm",
        "step": 12,
        "toolName": "read_file"
      },
      {
        "source": "llm",
        "step": 12,
        "toolName": "read_file"
      },
      {
        "source": "llm",
        "step": 12,
        "toolName": "read_file"
      },
      {
        "source": "llm",
        "step": 13,
        "toolName": "write_file"
      },
      {
        "source": "llm",
        "step": 14,
        "toolName": "read_file"
      },
      {
        "source": "llm",
        "step": 15,
        "toolName": "grep_search"
      },
      {
        "source": "llm",
        "step": 16,
        "toolName": "write_file"
      },
      {
        "source": "llm",
        "step": 17,
        "toolName": "read_file"
      },
      {
        "source": "llm",
        "step": 18,
        "toolName": "write_file"
      },
      {
        "source": "fs",
        "toolName": "list_directory",
        "action": "list",
        "path": ".",
        "timestamp": "2026-02-13T16:53:29.422Z"
      },
      {
        "source": "fs",
        "toolName": "read_file",
        "action": "read",
        "path": "TASK.md",
        "timestamp": "2026-02-13T16:53:30.368Z"
      },
      {
        "source": "fs",
        "toolName": "list_directory",
        "action": "list",
        "path": "schemas",
        "timestamp": "2026-02-13T16:53:31.355Z"
      },
      {
        "source": "fs",
        "toolName": "read_file",
        "action": "read",
        "path": "schemas/study_overview.schema.json",
        "timestamp": "2026-02-13T16:53:32.252Z"
      },
      {
        "source": "fs",
        "toolName": "read_file",
        "action": "read",
        "path": "schemas/quantitative_findings.schema.json",
        "timestamp": "2026-02-13T16:53:33.396Z"
      },
      {
        "source": "fs",
        "toolName": "read_file",
        "action": "read",
        "path": "schemas/claim_audit.schema.json",
        "timestamp": "2026-02-13T16:53:34.795Z"
      },
      {
        "source": "fs",
        "toolName": "read_file",
        "action": "read",
        "path": "schemas/public_summary.schema.json",
        "timestamp": "2026-02-13T16:53:37.077Z"
      },
      {
        "source": "fs",
        "toolName": "read_file",
        "action": "read",
        "path": "input/report.md",
        "timestamp": "2026-02-13T16:53:38.073Z"
      },
      {
        "source": "fs",
        "toolName": "write_file",
        "action": "write",
        "path": "output/study_overview.json",
        "timestamp": "2026-02-13T16:53:42.622Z"
      },
      {
        "source": "fs",
        "toolName": "write_file",
        "action": "write",
        "path": "output/quantitative_findings.json",
        "timestamp": "2026-02-13T16:53:45.505Z"
      },
      {
        "source": "fs",
        "toolName": "write_file",
        "action": "write",
        "path": "output/claim_audit.json",
        "timestamp": "2026-02-13T16:53:48.593Z"
      },
      {
        "source": "fs",
        "toolName": "read_file",
        "action": "read",
        "path": "output/study_overview.json",
        "timestamp": "2026-02-13T16:53:53.439Z"
      },
      {
        "source": "fs",
        "toolName": "read_file",
        "action": "read",
        "path": "output/quantitative_findings.json",
        "timestamp": "2026-02-13T16:53:53.439Z"
      },
      {
        "source": "fs",
        "toolName": "read_file",
        "action": "read",
        "path": "output/claim_audit.json",
        "timestamp": "2026-02-13T16:53:53.439Z"
      },
      {
        "source": "fs",
        "toolName": "write_file",
        "action": "write",
        "path": "output/public_summary.json",
        "timestamp": "2026-02-13T16:53:56.776Z"
      },
      {
        "source": "fs",
        "toolName": "read_file",
        "action": "read",
        "path": "output/public_summary.json",
        "timestamp": "2026-02-13T16:53:58.087Z"
      },
      {
        "source": "fs",
        "toolName": "grep_search",
        "action": "search",
        "path": "output",
        "timestamp": "2026-02-13T16:54:03.547Z"
      },
      {
        "source": "fs",
        "toolName": "write_file",
        "action": "write",
        "path": "output/claim_audit.json",
        "timestamp": "2026-02-13T16:54:07.818Z"
      },
      {
        "source": "fs",
        "toolName": "read_file",
        "action": "read",
        "path": "output/claim_audit.json",
        "timestamp": "2026-02-13T16:54:09.521Z"
      },
      {
        "source": "fs",
        "toolName": "write_file",
        "action": "write",
        "path": "output/public_summary.json",
        "timestamp": "2026-02-13T16:54:15.537Z"
      }
    ]
  },
  "grader": {
    "model": "chatgpt-gpt-5.2",
    "value": {
      "verdict": "pass",
      "scores": {
        "faithfulness": 4,
        "coverage": 5,
        "usefulness": 5
      },
      "critical_issues": [],
      "summary": "The JSON outputs closely track the report’s study design (preclinical murine + retrospective human), cohort sizes (L19–L23), quantitative results (L28–L33), key conditional/negative controls (L36–L39), proposed mechanism (L41–L46), and major caveats about the human evidence (L49–L53) and the need for prospective trials (L55–L56). No fabricated numerical values are introduced, and the reported p-value (L30) is not overstated as causal. Line references provided are valid and correspond to the text"
    }
  }
}
